Mater researchers undertaking the largest-ever genetic association study of osteoporosis say the project may reveal new therapeutic opportunities for treating osteoporosis.
Osteoporosis – a disease in which the skeleton becomes fragile and prone to fracture – is one of Australia’s most common chronic diseases, affecting more than 1.2 million people.
Half of all women over 50 will suffer an osteoporosis-related bone fracture and a quarter of those who suffer a hip fracture are likely to die within six months.
The ³Ô¹ÏÍøÕ¾ Health and Medical Research Council today announced that it is awarding more than $1.58m to Mater Research to conduct the largest genetic association study of bone mineral density on hundreds of thousands of individuals.
Dr John Kemp, Mater Research’s Musculoskeletal Genomics Group Leader, said medicines used to treat osteoporosis can slow bone loss, and in some cases partially restore lost bone. However, a cure for osteoporosis has not yet been found.
“Osteoporosis remains a major health burden for society and considerable scope exists to identify and develop new therapeutics that can restore lost bone,” Dr Kemp said.
“Development of new therapeutics for osteoporosis has been hampered by a limited understanding of the genes that control bone, as well as the different cell types in which they function.
“Our study is likely to identify cellular and genetic mechanisms that control bone, and prioritize those that can be targeted by new therapeutics to restore the structural integrity of bone.”
Dr Kemp’s team will also develop a web-based platform that will allow the international research community to explore their data.
“Knowledge sharing is key to accelerating the development of new therapeutics for osteoporosis,” Dr Kemp said.
The NHMRC has also confirmed funding for two other major Mater Research projects:
Paediatric Non-Alcoholic Fatty Liver Disease (NAFLD)
Dr Sahar Keshvari, of the Chronic and Integrated Care research program, has received a $637,040 NHMRC Investigator grant towards her research on paediatric NAFLD.
NAFLD is predicted to affect 30 per cent of children by 2040. Dr Keshvari will investigate how to manipulate macrophages (immune system cells) to prevent NAFLD and develop new therapies to fight the disease among children.
Inflammatory Bowel Disease (IBD)
Associate Professor Jake Begun, Group Leader – Inflammatory Bowel Diseases Research, has received an NHRMC Ideas grant of $1.65m.
A/Prof Begun’s project aims to change the way IBD is treated by personalising treatments based on the gut microbiome that will improve the well-being of the 100,000 Australians who suffer from the condition.
A/Prof Begun said that Australia has among the highest incidence of IBD globally, however current treatments are a “one-size fits all” approach that only block the immune system and don’t benefit all patients.
“Inflammatory gut conditions, including IBD, are driven by interactions between a person’s gut bacteria and their immune system,” A/Prof Begun said.
“My project aims to create tailor-made treatments by profiling these interactions and treating patients with complementary, bacterial-derived compounds targeting their specific profile.”
